Laboratory of Mitochondrial Biogenesis, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
ReMedy International Research Agenda Unit, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
EMBO Mol Med. 2019 May;11(5). doi: 10.15252/emmm.201809561.
Nuclear and mitochondrial genome mutations lead to various mitochondrial diseases, many of which affect the mitochondrial respiratory chain. The proteome of the intermembrane space (IMS) of mitochondria consists of several important assembly factors that participate in the biogenesis of mitochondrial respiratory chain complexes. The present study comprehensively analyzed a recently identified IMS protein cytochrome oxidase assembly factor 7 (COA7), or RESpiratory chain Assembly 1 (RESA1) factor that is associated with a rare form of mitochondrial leukoencephalopathy and complex IV deficiency. We found that COA7 requires the mitochondrial IMS import and assembly (MIA) pathway for efficient accumulation in the IMS We also found that pathogenic mutant versions of COA7 are imported slower than the wild-type protein, and mislocalized proteins are degraded in the cytosol by the proteasome. Interestingly, proteasome inhibition rescued both the mitochondrial localization of COA7 and complex IV activity in patient-derived fibroblasts. We propose proteasome inhibition as a novel therapeutic approach for a broad range of mitochondrial pathologies associated with the decreased levels of mitochondrial proteins.
核和线粒体基因组突变导致各种线粒体疾病,其中许多影响线粒体呼吸链。线粒体膜间空间(IMS)的蛋白质组由几个重要的组装因子组成,这些因子参与线粒体呼吸链复合物的生物发生。本研究全面分析了最近鉴定的 IMS 蛋白细胞色素氧化酶组装因子 7(COA7),或与一种罕见形式的线粒体脑白质病变和复合物 IV 缺乏相关的 RESpiratory 链组装 1(RESA1)因子。我们发现 COA7 需要线粒体 IMS 导入和组装(MIA)途径才能有效地在 IMS 中积累。我们还发现致病性突变体版本的 COA7 比野生型蛋白导入得更慢,并且错误定位的蛋白质在细胞质中被蛋白酶体降解。有趣的是,蛋白酶体抑制挽救了患者来源的成纤维细胞中 COA7 的线粒体定位和复合物 IV 活性。我们提出蛋白酶体抑制作为一种新的治疗方法,用于与线粒体蛋白水平降低相关的广泛线粒体病理学。